Cancer

Cover image for Vol. 123 Issue 7

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.649

ISI Journal Citation Reports © Ranking: 2015: 26/213 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 144
  1. Original Articles

    1. Disease Site

      Melanoma
      A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)

      Kevin Kalinsky, Sandra Lee, Krista M. Rubin, Donald P. Lawrence, Anthony J. Iafrarte, Darell R. Borger, Kim A. Margolin, Mario M. Leitao Jr, Ahmad A. Tarhini, Henry B. Koon, Andrew L. Pecora, Anthony J. Jaslowski, Gary I. Cohen, Timothy M. Kuzel, Christopher D. Lao and John M. Kirkwood

      Version of Record online: 23 MAR 2017 | DOI: 10.1002/cncr.30663

      • image
      • image

      In this multicenter, cooperative-group, 2-stage, single-arm clinical trial, 7 of 73 evaluable patients (9.6%) with mucosal, acral, vulvovaginal, or chronically sun-damaged melanoma achieved a partial response (wild-type KIT, 3 of 42; KIT mutation, 4 of 25; and unknown KIT status, 0 of 6). The dasatinib response rate among KIT-mutant melanoma patients is lower than anticipated.

    2. Breast Disease
      Are there patients with T1 to T2, lymph node-negative breast cancer who are “high-risk” for locoregional disease recurrence?

      Anita Mamtani, Sujata Patil, Michelle M. Stempel and Monica Morrow

      Version of Record online: 23 MAR 2017 | DOI: 10.1002/cncr.30658

      • image
      • image

      Among 657 patients with T1 to T2N0 breast cancer with ≥ 1 high-risk features (age < 40 years, lymphovascular invasion, high grade, multifocality/multicentricity, and a central/medial tumor location) who were treated with mastectomy without postmastectomy radiotherapy, the locoregional disease recurrence rate is 4.7%. Tumor size and receipt of systemic therapy are predictive (hazard ratios of 1.7 and 0.40, respectively), but no high-risk features appear to confer an increased risk of locoregional disease recurrence either independently or together.

  2. Erratum

    1. You have free access to this content
      Erratum

      Version of Record online: 23 MAR 2017 | DOI: 10.1002/cncr.30542

  3. Original Articles

    1. Discipline

      Clinical Trials
      Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate

      Christine B. Mackay, Kaitlyn R. Antonelli, Suanna S. Bruinooge, Jarron M. Saint Onge and Shellie D. Ellis

      Version of Record online: 23 MAR 2017 | DOI: 10.1002/cncr.30689

      • image
      • image

      Insurance denials for participation in adult cancer clinical trials continue despite the Affordable Care Act's clinical trial policy. Both academic and community research sites have experienced insurance denials and delays as barriers to patient enrollment.

  4. Review Articles

    1. Risk-reducing salpingectomy: Let us be opportunistic

      Kara C. Long Roche, Nadeem R. Abu-Rustum, Mlica Nourmoussavi and Oliver Zivanovic

      Version of Record online: 23 MAR 2017 | DOI: 10.1002/cncr.30528

      Evidence points increasingly to the fallopian tube as the site of origin for a significant majority of high-grade serous carcinomas. The current findings are reviewed with respect to bilateral salpingectomy, in both high-risk and average-risk populations, as a preventive measure that may reduce mortality while preserving ovarian function.

  5. Editorials

    1. Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?

      Goli Samimi and Lori M. Minasian

      Version of Record online: 23 MAR 2017 | DOI: 10.1002/cncr.30525

      • image

      A report in this issue of Cancer reviews the concept of bilateral salpingectomy as a preventive approach for high-grade serous carcinomas and describes the potential for risk reduction while limiting adverse effects of premature menopause that occur after salpingo-oophorectomy. The findings indicate that salpingectomy for risk-reduction in high-risk women remains a source of debate and requires additional research, particularly with respect to the role of the ovary in ovarian cancer progression.See also pages 000-000.

  6. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

      Arnon Nagler, Myriam Labopin, Dietrich Beelen, Fabio Ciceri, Liisa Volin, Avichai Shimoni, Roberto Foá, Noel Milpied, Jacopo Peccatori, Emmanuelle Polge, Audrey Mailhol, Mohamad Mohty and Bipin N. Savani

      Version of Record online: 22 MAR 2017 | DOI: 10.1002/cncr.30646

      • image

      A treosulfan-based conditioning regimen provides acceptable long-term survival with a low risk of early organ toxicity and acute graft-versus-host disease. The objective of future studies should be to compare treosulfan with the currently available ablative regimens and to define the best treosulfan combinations.

  7. Review Articles

    1. Acute lymphoblastic leukemia in adolescents and young adults

      Michael E. Rytting, Elias J. Jabbour, Susan M. O'Brien and Hagop M. Kantarjian

      Version of Record online: 22 MAR 2017 | DOI: 10.1002/cncr.30624

      Adolescent and young adult patients with acute lymphoblastic leukemia represent a distinct subgroup of patients who require specialized care. New treatment options, including therapy based on pediatric protocols, currently are being evaluated to improve outcomes.

  8. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning

      Orhan Kemal Yucel, Rima M. Saliba, Gabriella Rondon, Sairah Ahmed, Amin Alousi, Qaiser Bashir, Stefan O. Ciurea, Uday Popat, Isa Khouri, David Marin, Katy Rezvani, Partow Kebriaei, Elizabeth J. Shpall, Richard E. Champlin and Betül Oran

      Version of Record online: 21 MAR 2017 | DOI: 10.1002/cncr.30632

      • image
      • image
      • image
      • image

      Outcome data in older myelodysplastic syndrome (MDS) patients with allogeneic stem cell transplantation is limited, hence we investigated the outcomes in this population with the use of reduced intensity conditioning. Survival after hematopoietic stem cell transplantation (HSCT) depends on cytogenetics and hematopoietic cell transplantation–comorbidity index in older MDS patients, and decisions to proceed with HSCT should take these factors into account.

    2. Discipline

      Radiation Oncology
      The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma

      Yi An, Henry S. Park, Jacqueline R. Kelly, John M. Stahl, Wendell G. Yarbrough, Barbara A. Burtness, Joseph N. Contessa, Roy H. Decker, Matthew Koshy and Zain A. Husain

      Version of Record online: 21 MAR 2017 | DOI: 10.1002/cncr.30598

      • image
      • image
      • image
      • image

      The presence of extranodal extension in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma is correlated with inferior survival. However, adjuvant chemoradiation, compared with adjuvant radiotherapy alone, in a subgroup of patients with extranodal extension does not produce a detectable benefit.

  9. Review Articles

    1. You have full text access to this OnlineOpen article
      Treatment pathway of bone sarcoma in children, adolescents, and young adults

      Damon R. Reed, Masanori Hayashi, Lars Wagner, Odion Binitie, Diana A. Steppan, Andrew S. Brohl, Eric T. Shinohara, Julia A. Bridge, David M. Loeb, Scott C. Borinstein and Michael S. Isakoff

      Version of Record online: 21 MAR 2017 | DOI: 10.1002/cncr.30589

      • image
      • image
      • image
      • image

      This review presents a pathway for the management of common clinical scenarios that arise in the treatment of bone sarcomas in children, adolescents, and young adults. Clinical trials should be prioritized when they are available, and for those times when trials are unavailable, a consensus, multidisciplinary management approach to bone sarcomas is presented.

  10. Original Articles

    1. Discipline

      Clinical Trials
      Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621

      Mark D. Hurwitz, Jonathan Harris, Oliver Sartor, Ying Xiao, Bobby Shayegan, Paul W. Sperduto, Kasra R. Badiozamani, Colleen A. F. Lawton, Eric M. Horwitz, Jeff M. Michalski, Kevin Roof, David C. Beyer, Qiang Zhang and Howard M. Sandler

      Version of Record online: 21 MAR 2017 | DOI: 10.1002/cncr.30620

      • image
      • image

      The addition of docetaxel and androgen-deprivation therapy to adjuvant radiation therapy for men at high-risk of failure, despite receipt of both surgery and radiation therapy, results in a significant improvement in 3-year freedom from progression compared with historic controls who receive radiation alone. The individual contribution of hormone therapy and docetaxel in this setting will require additional appropriately designed, prospective, randomized studies.

    2. Disease Site

      Breast Disease
      Survival benefit needed to undergo chemotherapy: Patient and physician preferences

      Ines Vaz-Luis, Anne O'Neill, Karen Sepucha, Kathy D. Miller, Emily Baker, Chau T. Dang, Donald W. Northfelt, Eric P. Winer, George W. Sledge, Bryan Schneider and Ann H. Partridge

      Version of Record online: 21 MAR 2017 | DOI: 10.1002/cncr.30671

      • image
      • image

      Among patients who receive contemporary adjuvant chemotherapy, there is substantial variation in preferences regarding survival benefit worth undergoing adjuvant chemotherapy. Engaging patients preferences regarding risks/benefits of treatment is critical in patient-centered medical decision making and care.

  11. Review Articles

    1. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies

      Kalen J. Rimar, Phuoc T. Tran, Richard S. Matulewicz, Maha Hussain and Joshua J. Meeks

      Version of Record online: 21 MAR 2017 | DOI: 10.1002/cncr.30631

      • image
      • image

      There is an increasing appreciation that genitourinary (GU) malignancies, including bladder and especially prostate cancer, contain subsets of patients with germline and somatic alterations in homologous recombination genes that may reflect increased response to polyadenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors. In this review, the authors describe the mechanisms and rationale of PARP inhibitor use in patients with GU cancers, summarize previously reported preclinical and clinical trials, and identify ongoing trials to determine how PARP inhibitors and strategies targeted at homologous recombination repair can be applied for widespread application among patients with GU cancers.

  12. Original Articles

    1. Discipline

      Psychosocial Oncology
      Cancer in adolescents and young adults: Who remains at risk of poor social functioning over time?

      Olga Husson, Bradley J. Zebrack, Christine Aguilar, Brandon Hayes-Lattin and Steve Cole

      Version of Record online: 20 MAR 2017 | DOI: 10.1002/cncr.30656

      • image
      • image

      Nearly one-third of adolescent and young adult patients with cancer remain at risk of poor social functioning 24 months after their primary diagnosis. Reducing physical symptoms and psychological distress and enhancing social support by intervention during the period after treatment may potentially help these young survivors to better reintegrate into society.

    2. Outcomes Research
      The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer

      Bruce L. Jacobs, Jonathan G. Yabes, Samia H. Lopa, Dwight E. Heron, Chung-Chou H. Chang, Florian R. Schroeck, Justin E. Bekelman, Jeremy M Kahn, Joel B. Nelson and Amber E. Barnato

      Version of Record online: 16 MAR 2017 | DOI: 10.1002/cncr.30574

      • image
      • image
      • image

      There is a stark contrast in the adoption rates of intensity-modulated radiotherapy and stereotactic body radiation treatment for prostate cancer at the time of their introduction. Further investigation of the nonclinical factors associated with this difference is warranted.

    3. Safety and Quality
      Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry

      N. Lynn Henry, Thomas M. Braun, Tara M. Breslin, David H. Gorski, Samuel M. Silver and Jennifer J. Griggs

      Version of Record online: 16 MAR 2017 | DOI: 10.1002/cncr.30674

      • image
      • image

      Use of advanced imaging at the time of diagnosis of stage 0-IIA breast cancer decreased between 2008 and 2015 in a large statewide collaborative and remained stable for stage IIB disease. This decrease in testing over time resulted in a cost savings, especially for patients with stage I disease.

    4. Disease Site

      Genitourinary Disease
      Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives

      Xiao Min Wan, Liu Bao Peng, Jin An Ma and Yuan Jian Li

      Version of Record online: 16 MAR 2017 | DOI: 10.1002/cncr.30666

      • image
      • image
      • image
      • image

      In the United States, nivolumab is unlikely to be a high-value treatment for metastatic renal cell carcinoma at the current price, and a price reduction appears to be justified. When the drug is approved in China, value-based prices for the cost of nivolumab will be $7.90 and $9.70/mg for the country and Beijing City, respectively.

    5. Discipline

      Clinical Trials
      Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial

      Ying-Jun Chang, Yu Wang, Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Yao Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu and Xiao-Jun Huang

      Version of Record online: 16 MAR 2017 | DOI: 10.1002/cncr.30540

      • image
      • image
      • image
      • image

      Considerable progress has been made in unmanipulated haploidentical hematopoietic stem cell transplantation with an antithymocyte globulin (ATG)-based conditioning regimen. The findings of the current study suggest that ATG at a dose of 10 mg/kg is associated with better prevention of graft-versus-host disease and superior graft-versus-host disease-free/recurrence-free survival, but an increased rate of infection-related deaths. The optimal dose of ATG in the setting of unmanipulated haploidentical hematopoietic stem cell transplantation should be investigated further.

    6. Epidemiology
      Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: Results from a population-based analysis of 10,794 cases

      Linda Sharp, Joseph McDevitt, Christopher Brown, Anne-Elie Carsin and Harry Comber

      Version of Record online: 15 MAR 2017 | DOI: 10.1002/cncr.30583

      Compared with never smokers, current smokers at diagnosis have a significantly increased rate of death from cancer. The effect of current smoking is not modified by age or receipt of tumor-directed surgery, radiotherapy, or chemotherapy, but is slightly stronger in men than women.

    7. Body mass index, PAM50 subtype, recurrence and survival among patients with nonmetastatic breast cancer

      Elizabeth M. Cespedes Feliciano, Marilyn L. Kwan, Lawrence H. Kushi, Wendy Y. Chen, Erin K. Weltzien, Adrienne L. Castillo, Carol Sweeney, Philip S. Bernard and Bette J. Caan

      Version of Record online: 13 MAR 2017 | DOI: 10.1002/cncr.30637

      • image
      • image

      In the largest prospective study to examine the association of obesity and breast cancer outcomes separately by PAM50 subtype, extreme obesity doubles the risk of breast cancer death among women with luminal A tumors, and there is no association of body mass index and breast cancer outcomes for other subtypes. Future research should investigate the potential of a precision oncology approach that targets lifestyle intervention according to individual characteristics of the patient and disease.

    8. Disease Site

      Head and Neck Disease
      You have full text access to this OnlineOpen article
      TRAF3/CYLD mutations identify a distinct subset of human papilloma virus-associated head and neck squamous cell carcinoma

      Michael Hajek, Andrew Sewell, Susan Kaech, Barbara Burtness, Wendell G. Yarbrough and Natalia Issaeva

      Version of Record online: 13 MAR 2017 | DOI: 10.1002/cncr.30570

      • image
      • image
      • image
      • image
      • image
      • image

      Human papillomavirus-associated head and neck cancer tends to respond better to treatment compared with tobacco-associated tumors; however, patients suffer severe and long-lasting side effects. Somatic mutations in the genes TRAF3 and CYLD identified in The Cancer Genome Atlas data set are correlated with the activation of nuclear factor-κB, define a distinct etiologic subset of head and neck cancers, and will be useful as biomarkers for predicting improved prognosis and selecting patients with human papillomavirus-positive head and neck cancer who may be successfully treated with de-escalating therapy. See also pages 000-000.

  13. Editorial

    1. Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus

      Tony Chen, Jialing Zhang, Zhong Chen and Carter Van Waes

      Version of Record online: 13 MAR 2017 | DOI: 10.1002/cncr.30659

      Recent genomic studies of head and neck squamous cell carcinoma by The Cancer Genome Atlas as well as other groups identified deletions or mutations in tumor necrosis factor receptor-associated factor 3 (TRAF3) and cylindromatosis lysine 63 deubiquitinase (CYLD) that previously were implicated in nuclear factor-κB (NF-κB) and antiviral interferon responses. In this issue, Hajek et al find genomic alterations in TRAF3/CYLD define distinct subsets of human papillomavirus-positive head and neck squamous cell carcinomas with associated activation of transcription factor NF-κB, episomal human papillomavirus infection of tumors, and improved patient survival. See also pages 000-000.

  14. Original Articles

    1. Disease Site

      Hematologic Malignancies
      [18F]-FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study

      Ur Metser, Jill Dudebout, Tara Baetz, David C. Hodgson, Deanna L. Langer, Pamela MacCrostie, Victor Mak and Noam Tau

      Version of Record online: 13 MAR 2017 | DOI: 10.1002/cncr.30672

      Positron emission tomography/computed tomography (PET/CT) has a significant impact on staging and management in patients with apparent limited stage indolent lymphoma who are being considered for curative radiotherapy. PET/CT should be routinely incorporated into the workup of these patients.

    2. Breast Disease
      Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer

      Heather Y. Lin, Isabelle Bedrosian, Gildy V. Babiera, Simona F. Shaitelman, Henry M. Kuerer, Wendy A. Woodward, Naoto T. Ueno and Yu Shen

      Version of Record online: 13 MAR 2017 | DOI: 10.1002/cncr.30660

      • image

      Facility-level rather than patient-level factors appear to contribute disproportionately to the underuse of trimodality therapy among patients with nonmetastatic inflammatory breast cancer. To improve treatment guideline adherence for these patients, it is critical to identify the specific facility-level factors associated with the underuse of trimodality therapy.

  15. Review Articles

    1. Total neoadjuvant therapy for rectal cancer: An emerging option

      Ethan B. Ludmir, Manisha Palta, Christopher G. Willett and Brian G. Czito

      Version of Record online: 10 MAR 2017 | DOI: 10.1002/cncr.30600

      Total neoadjuvant therapy is emerging as an option to improve compliance, toxicity, disease control, and survival for patients with locally advanced rectal cancer. Multiple recently published prospective trials have demonstrated promising results with total neoadjuvant therapy approaches, which are highlighted in this review.

  16. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma—A quality-adjusted time without symptoms of progression or toxicity analysis

      Vincent Berry, Laurent Basson, Emilie Bogart, Olivier Mir, Jean-Yves Blay, Antoine Italiano, François Bertucci, Christine Chevreau, Stéphanie Clisant-Delaine, Bernadette Liegl-Antzager, Emmanuelle Tresch-Bruneel, Jennifer Wallet, Sophie Taieb, Emilie Decoupigny, Axel Le Cesne, Thomas Brodowicz and Nicolas Penel

      Version of Record online: 10 MAR 2017 | DOI: 10.1002/cncr.30661

      • image

      In patients with doxorubicin-pretreated nonadipocytic soft-tissue sarcoma, regorafenib significantly improves quality-adjusted survival in comparison with a placebo (8.0 vs 5.7 mo; P < .001).See also pages 000-000.

  17. Editorials

    1. Q-TWiST: What really matters to the cancer patient?

      Olga Husson and Robin L. Jones

      Version of Record online: 10 MAR 2017 | DOI: 10.1002/cncr.30662

      The quality-adjusted time without symptoms of disease or toxicity method improves on the current benchmarks of overall and progression-free survival by adding adverse events and utility coefficients to account for patients' quality of life. This will provide patients and their caregivers with additional information critical to making treatment decisions.See also pages 000-000.

  18. Original Articles

    1. Discipline

      Survivorship
      Posttreatment trajectories of physical activity in breast cancer survivors

      Alexander R. Lucas, Beverly J. Levine and Nancy E. Avis

      Version of Record online: 8 MAR 2017 | DOI: 10.1002/cncr.30641

      • image

      Without intervention, a large number of breast cancer survivors remain physically inactive after treatment. This group of survivors has a higher body mass index and lower physical functioning and less vitality compared with more active survivors.

    2. Pediatric Oncology
      Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy

      Mariko Sato, Jillian R. Gunther, Anita Mahajan, Eunji Jo, Arnold C. Paulino, Adekunle M. Adesina, Jeremy Y. Jones, Leena M. Ketonen, Jack M. Su, M. Fatih Okcu, Soumen Khatua, Robert C. Dauser, William E. Whitehead, Jeffrey Weinberg and Murali M. Chintagumpala

      Version of Record online: 7 MAR 2017 | DOI: 10.1002/cncr.30623

      • image
      • image
      • image

      This study compares patients with intracranial ependymomas treated with either intensity-modulated radiation therapy or proton-beam radiation therapy. The analysis suggests that local control is not compromised by the use of proton-beam radiation therapy, and gross total resection appears to confer better progression-free survival to those who have received proton-beam radiation therapy.

    3. Psychosocial Oncology
      Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome

      Diana D. Shi, David P. Yuppa, Trevor Dutton, Lauren K. Brais, Sarah L. Minden, Ilana M. Braun, Matthew H. Kulke, Jennifer A. Chan and Fremonta L. Meyer

      Version of Record online: 7 MAR 2017 | DOI: 10.1002/cncr.30633

      • image

      In the current study, the authors report that <10% of patients with neuroendocrine tumors with known carcinoid syndrome experience worsened carcinoid symptoms after the initiation of serotonergic medications. Serotonergic medications appear to be safe options for the treatment of symptoms of depression and anxiety in the majority of patients with neuroendocrine tumors and carcinoid syndrome.

    4. Disease Site

      Breast Disease
      Real-world impact of non–breast cancer–specific death on overall survival in resectable breast cancer

      Jianfei Fu, Lunpo Wu, Mengjie Jiang, Dan Li, Ting Jiang, Wei Fu, Liangjing Wang and Jinlin Du

      Version of Record online: 7 MAR 2017 | DOI: 10.1002/cncr.30617

      • image
      • image
      • image

      Overall survival is based on the absolute risk of death and does not take into account competing causes of death, which can be largely diluted by non–breast cancer–specific deaths during early breast cancer. For some future clinical trial planning, especially for old patients and patients with hormone receptor–positive breast cancer, non–breast cancer–specific death should be considered as a competing risk event.

    5. Discipline

      Survivorship
      Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry

      Fang Fang Zhang, Danielle E. Haslam, Mary Beth Terry, Julia A. Knight, Irene L. Andrulis, Mary B. Daly, Saundra S. Buys and Esther M. John

      Version of Record online: 6 MAR 2017 | DOI: 10.1002/cncr.30615

      • image

      Higher dietary intake of isoflavone in women with breast cancer is associated with reduced total mortality. This reduction is largely confined to women who have estrogen receptor-negative/progesterone receptor-negative tumors and those who do not receive hormone therapy as part of cancer treatment. See also pages 000-000.

  19. Editorial

    1. Soy foods, isoflavones, and breast cancer

      Omer Kucuk

      Version of Record online: 6 MAR 2017 | DOI: 10.1002/cncr.30614

      Recent data from Asia and North America indicate that soy foods may decrease the risk of breast cancer and improve the results of treatment in patients with breast cancer. Studying soy foods and isoflavones promises to be an exceptionally fertile area for a wide range of cancer researchers. See also pages 000-000.

  20. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Cardiomyopathy in patients after posttransplant cyclophosphamide–based hematopoietic cell transplantation

      Chien-Jung Lin, Justin M. Vader, Michael Slade, John F. DiPersio, Peter Westervelt and Rizwan Romee

      Version of Record online: 6 MAR 2017 | DOI: 10.1002/cncr.30534

      • image
      • image
      • image
      • image

      Mild pretransplant cardiomyopathy, found in 9.1% of transplants, does not affect overall survival. New-onset cardiomyopathy, found in 21.9% of patients undergoing posttransplant cyclophosphamide–based hematopoietic cell transplantation, occurs in an infective milieu and is associated with decreased survival.

  21. Editorial

    1. Chemotherapy-induced neuropathy: Central resolution of a peripherally perceived problem?

      Elizabeth J. Cathcart-Rake, Daniel R. Hilliker and Charles L. Loprinzi

      Version of Record online: 3 MAR 2017 | DOI: 10.1002/cncr.30650

      Although chemotherapy-induced neuropathy is perceived as a peripheral nervous system problem, data suggest that it may be ameliorated by addressing central nervous system functions. See also pages 000-000.

  22. Original Articles

    1. Discipline

      Clinical Trials
      Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study

      Sarah Prinsloo, Diane Novy, Larry Driver, Randall Lyle, Lois Ramondetta, Cathy Eng, Jennifer McQuade, Gabriel Lopez and Lorenzo Cohen

      Version of Record online: 3 MAR 2017 | DOI: 10.1002/cncr.30649

      • image
      • image

      Neuromodulatory interventions could be a novel modality for patients trying to manage symptoms of chemotherapy-induced peripheral neuropathy, but they are not yet the standard of care. Therefore, this article examines whether electroencephalogram neurofeedback can alleviate symptoms of chemotherapy-induced peripheral neuropathy in survivors. A randomized controlled trial shows that neurofeedback is effective at reducing pain and other symptoms of chemotherapy-induced peripheral neuropathy. See also pages 000-000.

  23. Insight from the Experts

    1. Using cancer genomics to guide clinical decisions

      Mark E. Burkard, Dustin A. Deming and Josh Lauring

      Version of Record online: 2 MAR 2017 | DOI: 10.1002/cncr.30640

      • image

      Genomic tests now provide unprecedented insight into what drives cancer; however, using this information in the clinic remains a challenge. This article provide insights into interpreting and using genomic tests for clinical decisions based on experience in leading molecular tumor boards.

  24. Original Articles

    1. Discipline

      Epidemiology
      The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer

      Carole Fakhry, William H. Westra, Steven J. Wang, Annemieke van Zante, Yuehan Zhang, Eleni Rettig, Linda X. Yin, William R. Ryan, Patrick K. Ha, Alicia Wentz, Wayne Koch, Jeremy D. Richmon, David W. Eisele and Gypsyamber D'Souza

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30353

      • image
      • image

      Among patients with oropharyngeal squamous cell cancer, the risk of death is reduced not only with human papillomavirus positivity (adjusted hazard ratio, 0.44; P = .007) but also for women versus men (adjusted hazard ratio, 0.55; P = .04). In contrast, among patients with nonoropharyngeal head and neck squamous cell cancer, the human papillomavirus tumor status (P = .77), p16 (P = .26), and sex (P = .35) have no impact on overall survival.

  25. Commentary

    1. The complex relation between race, sex, and human papillomavirus status in head and neck cancer

      Jose P. Zevallos and Angela L. Mazul

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30619

      This study demonstrates that sex affects the prognosis differentially in oropharyngeal cancer and nonoropharyngeal cancer. The authors also find that race does not affect survival in oropharyngeal cancer after adjustments for the human papillomavirus status. See also pages 000-000.

  26. Original Articles

    1. Discipline

      Disparities Research
      Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers

      Elysia Alvarez, Theresa Keegan, Emily E. Johnston, Robert Haile, Lee Sanders, Olga Saynina and Lisa J. Chamberlain

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30562

      • image
      • image

      The findings from this study reveal an overall increase in the use of specialized cancer center over time, but the trend is not experienced equally. Adolescents and young adults with disparate access to specialty cancer care are older, have public or no health insurance, are of Hispanic race/ethnicity, and reside farther from a specialized cancer center.

    2. Disease Site

      Head and Neck Disease
      Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer

      Evan M. Graboyes, Elizabeth Garrett-Mayer, Anand K. Sharma, Eric J. Lentsch and Terry A. Day

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30651

      • image
      • image
      • image

      In a review of the National Cancer Data Base, more than 50% of patients with head and neck squamous cell carcinoma who undergo surgery and postoperative radiation therapy receive care that does not adhere to National Comprehensive Cancer Network guidelines with regard to initiating postoperative radiation therapy within 6 weeks of surgery. Sociodemographic, oncologic, treatment, and hospital factors are all associated with failure to receive guideline-directed care and should be explored in future studies.

    3. Discipline

      Epidemiology
      Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area

      Zhiwei Liu, Ellen T. Chang, Qing Liu, Yonglin Cai, Zhe Zhang, Guomin Chen, Qi-Hong Huang, Shang-Hang Xie, Su-Mei Cao, Jian-Yong Shao, Wei-Hua Jia, Yuming Zheng, Jian Liao, Yufeng Chen, Longde Lin, Liming Liang, Ingemar Ernberg, Thomas L. Vaughan, Hans-Olov Adami, Guangwu Huang, Yi Zeng, Yi-Xin Zeng and Weimin Ye

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30643

      • image

      In this population-based case-control study of 2499 cases of nasopharyngeal carcinoma and 2576 controls, the excess risk appears to be higher for a maternal than a paternal history and slightly stronger for a sibling compared with a parental history and for a sororal than a fraternal history. Among relatives of cases, the cumulative risk of nasopharyngeal carcinoma up to age 74 years is reported to be 3.7%, whereas that among relatives of controls is 0.9%.

    4. Disease Site

      Hematologic Malignancies
      Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

      Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Zhengjia Chen, Amelia A. Langston, Brittany Hill, Martha Arellano, Fuad El-Rassi, Audrey Kim, Anand Jillella, Vamsi K. Kota, Imre Bodó and Hanna Jean Khoury

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30608

      • image
      • image
      • image

      Less frequent monitoring of BCR-ABL1 after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia does not appear to affect outcomes. The discontinuation of tyrosine kinase inhibitors used as first-line treatment or beyond after resistance or intolerance to first-line treatment appears to be feasible.

  27. Review Articles

    1. Immune checkpoint inhibitors in challenging populations

      Douglas B. Johnson, Ryan J. Sullivan and Alexander M. Menzies

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30642

      Immune checkpoint inhibitors provide durable responses for many patients with cancer, but they have not been extensively tested in many patient populations. This article reviews the safety and activity of these agents in challenging patient populations, including patients with autoimmune diseases, patients with organ dysfunction, patients at extremes of age, pregnant patients, and patients with brain metastases.

  28. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma

      Shinji Miwa, Hideji Nishida, Yoshikazu Tanzawa, Akihiko Takeuchi, Katsuhiro Hayashi, Norio Yamamoto, Eishiro Mizukoshi, Yasunari Nakamoto, Shuichi Kaneko and Hiroyuki Tsuchiya

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30606

      • image
      • image
      • image
      • image
      • image

      In a phase 1/2 trial of immunotherapy using dendritic cells pulsed with autologous tumor lysate and OK-432, dendritic cell–based immunotherapy activates the immune responses of patients without the severe adverse effects associated with the immunotherapy. The data indicate that a regimen consisting of dendritic cell immunotherapy using tumor lysate and OK-432 is safe and induces immunological responses in patients with refractory sarcoma; however, an improvement in clinical outcomes is seen in only a small number of patients. See also pages 000-000.

    2. Discipline

      Epidemiology
      Future of testicular germ cell tumor incidence in the United States: Forecast through 2026

      Armen A. Ghazarian, Scott P. Kelly, Sean F. Altekruse, Philip S. Rosenberg and Katherine A. McGlynn

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30597

      • image
      • image
      • image

      Between 2013 and 2026, testicular germ cell tumor incidence rates among Hispanic men are forecast to increase by 3.96% annually, the highest rate of increase among any racial/ethnic group in the United States. By 2026, the highest testicular gem cell tumor rates in the United States will be among Hispanics because of the rising incidence among recent birth cohorts.

  29. Editorial

    1. Potential of immunotherapy for sarcoma

      Robert M. Hoffman, Arun S. Singh and Fritz C. Eilber

      Version of Record online: 27 FEB 2017 | DOI: 10.1002/cncr.30603

      This editorial examines Miwa et al's article entitled “Phase 1/2 Study of Immunotherapy With Dendritic Cells Pulsed With Autologous Tumor Lysate in Patients With Refractory Bone and Soft Tissue Sarcoma: A Safe Method for Inducing an Immunological Response but With Limited Effects on Clinical Outcomes,” which appears in the current issue of Cancer. The state of the art of autologous cancer vaccines is briefly reviewed, and suggestions for improved immunological therapy for sarcomas are discussed. See also pages 000-000.

  30. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials

      Xiaoyu Qu, Megan Othus, Jerry Davison, Yu Wu, Liying Yan, Soheil Meshinchi, Fabiana Ostronoff, Elihu H. Estey, Jerry P. Radich, Harry P. Erba, Frederick R. Appelbaum and Min Fang

      Version of Record online: 21 FEB 2017 | DOI: 10.1002/cncr.30626

      • image
      • image
      • image

      Hypomethylation of either leucine zipper tumor suppressor 2 (LZTS2) or nuclear receptor subfamily 6 group a member 1 (NR6A1) is associated with worse overall survival in patients with acute myeloid leukemia with normal cytogenetics. The prognostic impact appears to be independent of age, performance status, white blood cell and platelet counts, and Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) status.

    2. Discipline

      Outcomes Research
      Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study

      Neyssa M. Marina, Qi Liu, Sarah S. Donaldson, Charles A. Sklar, Gregory T. Armstrong, Kevin C. Oeffinger, Wendy M. Leisenring, Jill P. Ginsberg, Tara O. Henderson, Joseph P. Neglia, Marilyn A. Stovall, Yutaka Yasui, R. Lor Randall, David S. Geller, Leslie L. Robison and Kirsten K. Ness

      Version of Record online: 21 FEB 2017 | DOI: 10.1002/cncr.30627

      • image
      • image

      Ewing sarcoma survivors' risk for late mortality and subsequent neoplasms does not plateau. Treatment-related chronic conditions develop years after therapy, and this supports the need for lifelong follow-up.

    3. Clinical Trials
      Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma

      Julian Huang, Mark Fogg, Lori J. Wirth, Heather Daley, Jerome Ritz, Marshall R. Posner, Fred C. Wang and Jochen H. Lorch

      Version of Record online: 21 FEB 2017 | DOI: 10.1002/cncr.30541

      Early-stage and intermediate stage nasopharyngeal cancer generally carry a good prognosis, but for patients with recurrent, metastatic disease, treatment options are limited. A phase 1/2 study evaluating the efficacy of Epstein-Barr virus-stimulated cytotoxic T-lymphocyte immunotherapy demonstrates the potential for a durable response, but further research is necessary to increase the efficacy of this immunotherapy in the population of patients with incurable nasopharyngeal cancer.

  31. Commentary

    1. Meaningful endpoints for therapies approved for hematologic malignancies

      B. Douglas Smith, Amy E. DeZern, Alex W. Bastian and Brian G. M. Durie

      Version of Record online: 21 FEB 2017 | DOI: 10.1002/cncr.30622

      • image

      This retrospective review indicates that US Food and Drug Administration approvals of treatments for hematologic malignancies often include endpoints other than overall survival, such as progression-free survival and response rate. Effective assessment of the value of treatment options should be made with a clear understanding of appropriate outcomes for hematologic malignancies and realistic expectations regarding the nature and magnitude of meaningful benefit.

  32. Original Articles

    1. Disease Site

      Breast Disease
      Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis

      Stephanie M. Wong, Natasha K. Stout, Rinaa S. Punglia, Ipshita Prakash, Yasuaki Sagara and Mehra Golshan

      Version of Record online: 21 FEB 2017 | DOI: 10.1002/cncr.30644

      • image

      Women diagnosed with lobular carcinoma in situ have a 3-fold to 10-fold increased risk of developing invasive breast cancer. In this analysis, a Markov simulation model is used to evaluate the overall and quality-adjusted life expectancies and survival differences offered by active surveillance, risk-reducing chemoprevention, and bilateral prophylactic mastectomy, with results suggesting that prevention strategies only modestly affect overall survival in patients with lobular carcinoma in situ, whereas chemoprevention remains the preferred management strategy for optimizing invasive disease-free survival while prolonging quality-adjusted life expectancy.

    2. Discipline

      Survivorship
      Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States

      Zhiyuan Zheng, Xuesong Han, Gery P. Guy Jr, Amy J. Davidoff, Chunyu Li, Matthew P. Banegas, Donatus U. Ekwueme, K. Robin Yabroff and Ahmedin Jemal

      Version of Record online: 20 FEB 2017 | DOI: 10.1002/cncr.30560

      • image
      • image
      • image

      Cancer survivors in the United States are more likely to change their prescription drug use for financial reasons than individuals without a cancer history. Survivors younger than 65 years and those who have multiple comorbid conditions are especially vulnerable to the financial burden associated with prescription drugs. See also pages 000-000.

  33. Editorial

    1. Financial toxicity in cancer care—Edging toward solutions

      Daniel A. Goldstein

      Version of Record online: 20 FEB 2017 | DOI: 10.1002/cncr.30555

      Financial toxicity is now a well established and generally accepted toxicity related to cancer care. While policy makers and politicians continue to debate about system-wide changes, physicians and patients can seek ways to decrease financial toxicity and to incorporate this issue into every decision-making process. See also pages 000-000.

  34. Original Articles

    1. Discipline

      Pediatric Oncology
      Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee

      Howard M. Katzenstein, Wayne L. Furman, Marcio H. Malogolowkin, Mark D. Krailo, M. Beth McCarville, Alexander J. Towbin, Greg M. Tiao, Milton J. Finegold, Sarangarajan Ranganathan, Stephen P. Dunn, Max R. Langham, Eugene D. McGahren, Carlos Rodriguez-Galindo and Rebecka L. Meyers

      Version of Record online: 17 FEB 2017 | DOI: 10.1002/cncr.30591

      • image
      • image
      • image
      • image
      • image
      • image

      The combination of vincristine and irinotecan appears to have substantial activity against high-risk hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with high-risk hepatoblastoma remains to be determined.

    2. Outcomes Research
      Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities

      Amikar Sehdev, Eric A. Sherer, Siu L. Hui, Jingwei Wu and David A. Haggstrom

      Version of Record online: 17 FEB 2017 | DOI: 10.1002/cncr.30569

      • image
      • image

      Among a minority of veterans who are survivors of colorectal cancer, both a lack of guideline-concordant computed tomography surveillance and potential overuse appear to be present. Patient factors, but not provider or organizational characteristics, are significantly associated with guideline-concordant care. The 2005 change in the American Society of Clinical Oncology guidelines does not appear to have an impact on rates of surveillance computed tomography.

    3. Disease Site

      Hematologic Malignancies
      Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT

      Jiří Pavlů, Myriam Labopin, Anna K. Zoellner, Ioanna Sakellari, Matthias Stelljes, Jürgen Finke, Renato Fanin, Gernot Stuhler, Boris V. Afanasyev, Adrian J. Bloor, Achilles Anagnostopoulos, Mohamad Mohty, Sebastian Giebel and Arnon Nagler

      Version of Record online: 17 FEB 2017 | DOI: 10.1002/cncr.30604

      • image

      The objective of the current study is to establish the outcomes of allogeneic hematopoietic cell transplantation in patients with primary refractory acute lymphoblastic leukemia and to identify factors potentially influencing these outcomes. With a median follow-up of 106 months, the probability of survival is reported to be 36% at 2 years and 23% at 5 years, with superior survival noted among patients who received total body irradiation and in male patients receiving hematopoietic cells from female donors.

    4. Discipline

      Pediatric Oncology
      Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

      David O. Walterhouse, Alberto S. Pappo, Jane L. Meza, John C. Breneman, Andrea Hayes-Jordan, David M. Parham, Timothy P. Cripe, James R. Anderson, William H. Meyer and Douglas S. Hawkins

      Version of Record online: 17 FEB 2017 | DOI: 10.1002/cncr.30613

      • image
      • image

      The primary goal of Children's Oncology Group ARST0331 for patients with subset 2 low-risk embryonal rhabdomyosarcoma is to reduce the total cumulative dose of cyclophosphamide without compromising failure-free survival. However, the authors report suboptimal failure-free survival in these patients using reduced total cyclophosphamide.

    5. Disease Site

      Breast Disease
      Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay

      Carlos H. Barcenas, Akshara Raghavendra, Arup K. Sinha, Masood Pasha Syed, Limin Hsu, Modesto G. Patangan Jr, Mariana Chavez-MacGregor, Yu Shen, Gabriel H. Hortobagyi, Vicente Valero, Sharon H. Giordano, Naoto T. Ueno and Debu Tripathy

      Version of Record online: 15 FEB 2017 | DOI: 10.1002/cncr.30618

      • image
      • image
      • image
      • image

      The current study demonstrates similar breast cancer-related outcomes with or without chemotherapy among patients with early-stage breast cancer with hormone receptor-positive, human epidermal growth factor receptor 2-negative, lymph node-negative disease who have tumors with a 21-gene recurrence score of 11 to 25 and receive adjuvant endocrine therapy. However, due to a relatively short follow-up and small number of outcome events herein, the benefit of chemotherapy cannot be ruled out in this group of patients.

    6. Discipline

      Supportive Care
      Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer

      Melissa K. Yee, Susan M. Sereika, Catherine M. Bender, Adam M. Brufsky, Mary C. Connolly and Margaret Q. Rosenzweig

      Version of Record online: 15 FEB 2017 | DOI: 10.1002/cncr.30575

      • image

      In the current study, African American women are found to experience a deterioration in overall symptom incidence, particularly over the course of chemotherapy from baseline (before chemotherapy) to the midpoint, which appears to be associated with less adherence to chemotherapy overall. Thus, the incidence and management of chemotherapy-related symptoms may be contributing to breast cancer dose disparity and should be explored further.

    7. Disparities Research
      Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment

      Jeffrey Peppercorn, Nora Horick, Kevin Houck, Julia Rabin, Victor Villagra, Gary H. Lyman and Stephanie B. Wheeler

      Version of Record online: 14 FEB 2017 | DOI: 10.1002/cncr.30629

      • image

      In a national sample of predominantly rural working-age women, the elimination of cost sharing for screening mammography correlates with up to a 6% increase in breast cancer screening rates.

    8. Disease Site

      Breast Disease
      A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors

      Maureen Sadim, Yanfei Xu, Katharina Selig, Julie Paulus, Regina Uthe, Surbhi Agarwl, Iram Dubin, Panagiota Oikonomopoulou, Lesya Zaichenko, Silvia Aki McCandlish, Linda Van Horn, Christos Mantzoros, Donna Pauler Ankerst and Virginia G. Kaklamani

      Version of Record online: 14 FEB 2017 | DOI: 10.1002/cncr.30628

      • image

      Weight gain after a diagnosis of breast cancer is a significant health hazard because of its impact on survival, breast cancer-specific survival, and quality of life. Women younger than 60 years at the time of breast cancer diagnosis who have an obesity genetic risk model have an increased risk of weight gain after treatment and should be targeted for weight-maintenance interventions.

    9. Discipline

      Epidemiology
      Early estimates of SEER cancer incidence, 2014

      Denise Riedel Lewis, Huann-Sheng Chen, Myles G. Cockburn, Xiao-Cheng Wu, Antoinette M. Stroup, Douglas N. Midthune, Zhaohui Zou, Martin F. Krapcho, Daniel G. Miller and Eric J. Feuer

      Version of Record online: 14 FEB 2017 | DOI: 10.1002/cncr.30630

      • image
      • image

      The current study presents a first look at rates and trends for cases in the Surveillance, Epidemiology, and End Results program diagnosed from 2000 through 2014 based on the February 2016 submission. A new variation of the statistical model to correct for incomplete reporting was added this year that demonstrated even better agreement between the prior February and November submissions and that the delay-adjusted February submission data can be used to produce valid estimates of incidence trends.

    10. Disease Site

      Breast Disease
      Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer

      Alana R. Donaldson, Shashirekha Shetty, Zhen Wang, Christine L. Rivera, Bryce P. Portier, G. Thomas Budd, Erinn Downs-Kelly, Christopher P. Lanigan and Benjamin C. Calhoun

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30592

      • image
      • image

      The use of an alternative chromosome 17 probe in fluorescence in situ hybridization for human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer results in the classification of more patients as eligible for HER2-targeted therapy. The benefit these patients derive from HER2-directed therapy is unproven.

    11. Discipline

      Pediatric Oncology
      Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics

      Liza-Marie Johnson, Jessica M. Valdez, Emily A. Quinn, April D. Sykes, Rose B. McGee, Regina Nuccio, Stacy J. Hines-Dowell, Justin N. Baker, Chimene Kesserwan, Kim E. Nichols and Belinda N. Mandrell

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30581

      Overall confidence in the interpretation, use, and discussion of oncology-based genomics results is low among pediatric oncologists, and a majority desire support from a genetic counselor before disclosing germline test results. Further research into the clinical integration of sequencing results into pediatric cancer care is warranted.

    12. Disease Site

      Hematologic Malignancies
      Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death

      Michael Lauseker, Joerg Hasford, Susanne Saussele, Stephan Kremers, Doris Kraemer, Walter Lindemann, Rüdiger Hehlmann, Markus Pfirrmann and for the German CML Study Group

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30636

      • image
      • image

      Smoking has been found to be a prognostically unfavorable factor in patients with chronic myeloid leukemia with regard to survival as well as progression to advanced phases of disease. Therefore, patients with chronic myeloid leukemia should receive adequate encouragement and support to quit smoking.

    13. Discipline

      Clinical Trials
      A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma

      Lipika Goyal, Hui Zheng, Matthew B. Yurgelun, Thomas A. Abrams, Jill N. Allen, James M. Cleary, Michelle Knowles, Eileen Regan, Amanda Reardon, Anna Khachatryan, Rakesh K. Jain, Valentina Nardi, Darrell R. Borger, Dan G. Duda and Andrew X. Zhu

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30571

      • image

      In a phase 2 trial in patients with advanced refractory cholangiocarcinoma, cabozantinib has demonstrated limited efficacy and significant toxicity. A biomarker analysis shows on-target antiangiogenic activity of cabozantinib, and baseline plasma-soluble MET correlates with overall survival. Any further development of this drug in cholangiocarcinoma should include dose reduction, a biomarker-driven approach, and the consideration of its combination with other drugs.

    14. Disease Site

      Neuro-Oncology
      Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies

      Jacob A. Miller, Rupesh Kotecha, Manmeet S. Ahluwalia, Alireza M. Mohammadi, Samuel T. Chao, Gene H. Barnett, Erin S. Murphy, Michael A. Vogelbaum, Lilyana Angelov, David M. Peereboom and John H. Suh

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30616

      • image
      • image

      Among patients who develop human epidermal growth factor receptor 2 (HER2)-amplified metastatic breast cancer, the brain is increasingly being recognized as a common site of disease recurrence, perhaps due to extended survival and the poor penetration of HER2-directed antibodies into the central nervous system. The authors report significantly extended survival and improved intracranial control with both HER2/epidermal growth factor receptor-directed tyrosine kinase inhibitors and HER2 antibodies, thereby supporting a paradigm of upfront stereotactic radiosurgery in combination with these agents, reserving whole-brain radiotherapy for salvage.

  35. Review Articles

    1. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

      Maximilian Stahl and Amer M. Zeidan

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30585

      • image

      Lenalidomide is an excellent option for red blood cell transfusion-dependent patients with myelosysplastic syndrome who have low to intermediate risk disease and harbor a deletion of the long arm of chromosome 5. Further research is needed to improve the predictive ability to select patients who are likely to respond to lenalidomide and investigative lenalidomide-based combination therapy approaches that are synergistic and do not have excessive toxicity.

  36. Original Articles

    1. Disease Site

      Head and Neck Disease
      Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials

      Lin Kong, Youwang Zhang, Chaosu Hu, Ye Guo and Jiade J. Lu

      Version of Record online: 13 FEB 2017 | DOI: 10.1002/cncr.30566

      • image
      • image

      Induction chemotherapy with docetaxel, platinum, and fluorouracil significantly improves the outcomes of patients with locally advanced nasopharyngeal cancer.

    2. Discipline

      Medical Oncology
      Determinants of the recommended phase 2 dose of molecular targeted agents

      Aaron R. Hansen, Natalie Cook, Eitan Amir, Lillian L. Siu and Albiruni Ryan Abdul Razak

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30579

      • image
      • image
      • image

      In the era of molecular targeted agents (MTAs), it is unclear whether toxicity is the optimal method for identifying a recommended phase 2 dose (RP2D). Phase 1 trials of monotherapy MTAs more frequently use nontoxicity parameters to define RP2D, and the use of such endpoints is significantly associated with a higher likelihood of regulatory approval for MTAs.

  37. Editorial

    1. Dose determination for molecularly targeted therapies: Much Ado About Nothing

      Anthony Tolcher

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30584

      Literature reviews and meta-analyses of phase 1 studies are particularly difficult to perform and rarely draw useful conclusions due to the small size of individual studies and the varied populations. With the low rate of success in oncology drug development, the focus should turn to improving the efficiency of phase 1 studies.

  38. Commentary

    1. Words matter: Restoring respect and dignity when referring to individuals with cancer

      Lee M. Ellis, Charles D. Blanke and Elise C. Kohn

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30625

      Respecting our patients is the first reassuring step in a long, shared journey during cancer therapy and beyond. The provision of excellent oncologic and medical care in the absence of empathy and respect undermines and compromises the potential value of any intervention.

  39. Review Articles

    1. You have free access to this content
      Improving access to high-cost cancer drugs in Latin America: Much to be done

      Rossana Ruiz, Kathrin Strasser-Weippl, Diego Touya, Carmen Herrero Vincent, Abraham Hernandez-Blanquisett, Jessica St. Louis, Alexandra Bukowski and Paul E. Goss

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30549

      Limited access to high-cost cancer medications poses a significant threat to global health care, particularly for low- and middle-income countries. Systematic and transparent cost-effectiveness analyses are needed to devise equitable oncology drug pricing schemes.

  40. Editorial

    1. You have free access to this content
      High cancer drug prices 4 years later—Progress and prospects

      Hagop Kantarjian and Yogin Patel

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30545

      High cancer drug prices continue to be a significant problem in the United States despite the existence of remedial solutions that can be readily implemented with appropriate legislations. See also pages 000-000.

  41. Original Articles

    1. Disease Site

      Head and Neck Disease
      Effect of postoperative radiotherapy on survival for surgically managed pT3N0 and pT4aN0 laryngeal cancer: Analysis of the National Cancer Data Base

      Evan M. Graboyes, Kevin Y. Zhan, Elizabeth Garrett-Mayer, Eric J. Lentsch, Anand K. Sharma and Terry A. Day

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30586

      • image
      • image
      • image

      In a review of the National Cancer Data Base of patients with surgically managed, pT3N0 laryngeal squamous cell carcinoma (SCC) with negative margins, the use of postoperative radiotherapy (PORT) does not appear to be associated with improved survival. Patients with pT4aN0 laryngeal SCC and negative margins have improved survival with PORT, but nearly 50% of patients with pT4aN0 laryngeal SCC do not receive standard-of-care PORT.

    2. Discipline

      Disparities Research
      Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors

      Deborah Cragun, Anne Weidner, Courtney Lewis, Devon Bonner, Jongphil Kim, Susan T. Vadaparampil and Tuya Pal

      Version of Record online: 9 FEB 2017 | DOI: 10.1002/cncr.30621

      • image
      • image
      • image

      Among BRCA carriers, the lower rates of risk-reducing salpingo-oophorectomy among blacks compared with Hispanics and non-Hispanic whites is concerning and may reduce benefits from genetic testing. Furthermore, lower rates of BRCA testing among blacks may be attributed in part to lower likelihood of provider discussion, suggesting the need to develop and implement multilevel interventions.

    3. Outcomes Research
      Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes

      Firas El Chaer, Dimpy P. Shah, Joumana Kmeid, Ella J. Ariza-Heredia, Chitra M. Hosing, Victor E. Mulanovich and Roy F. Chemaly

      Version of Record online: 8 FEB 2017 | DOI: 10.1002/cncr.30599

      • image
      • image

      Human metapneumovirus infections in patients with cancer may cause significant morbidity, especially in those with underlying hematologic malignancies who may develop a lower respiratory infection. Despite high morbidity and the lack of directed antiviral therapy for human metapneumovirus infections, mortality from this infection at day 30 and day 90 remains low in the studied population.

    4. Disease Site

      Neuro-Oncology
      Treatment trends for patients with brain metastases: Does practice reflect the data?

      Kiri A. Sandler, Narek Shaverdian, Ryan R. Cook, Amar U. Kishan, Christopher R. King, Isaac Yang, Michael L. Steinberg and Percy Lee

      Version of Record online: 8 FEB 2017 | DOI: 10.1002/cncr.30607

      • image
      • image
      • image
      • image

      A survey regarding treatment practices among patients with brain metastases was distributed to practicing radiation oncologists to determine how provider and patient characteristics influence treatment recommendations. The majority of providers, but especially central nervous system specialists or those who frequently treat patients with brain metastases, appear to be treating more patients with brain metastases using stereotactic radiosurgery than what is currently described in published practice guidelines, indicating a need for prospective studies to support this emerging practice pattern.

    5. Chest and Lung Disease
      Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma

      Kosuke Tanaka, Toyoaki Hida, Yuko Oya, Tatsuya Yoshida, Junichi Shimizu, Tetsuya Mizuno, Hiroaki Kuroda, Noriaki Sakakura, Kenichi Yoshimura, Yoshitsugu Horio, Yukinori Sakao and Yasushi Yatabe

      Version of Record online: 8 FEB 2017 | DOI: 10.1002/cncr.30539

      • image
      • image
      • image
      • image
      • image
      • image

      Lung adenocarcinoma in patients aged 40 years or younger has a distinctly unique prevalence of oncogenic genetic alterations. Comprehensive screening for driver genetic alterations is especially recommended in this population, because they tend to have more alterations that can be treated with existing targeted therapies.

    6. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel

      Andrew J. Armstrong, Fred Saad, De Phung, Carl Dmuchowski, Neal D. Shore, Karim Fizazi, Mohammad Hirmand, David Forer, Howard I. Scher and Johann De Bono

      Version of Record online: 7 FEB 2017 | DOI: 10.1002/cncr.30587

      • image
      • image
      • image
      • image

      A post hoc analysis of the randomized, double-blind AFFIRM trial revealed that postenzalutamide prostate-specific antigen declines of any, ≥30%, and ≥50% are associated with greater clinical and pain response. The decline criteria explain a large proportion of treatment effect on survival improvements but do not fulfill the criteria for surrogacy.

    7. Radiation Oncology
      A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck

      Bindu V. Manyam, Adam A. Garsa, Rei-I Chin, Chandana A. Reddy, Brian Gastman, Wade Thorstad, Sue S. Yom, Brian Nussenbaum, Steven J. Wang, Allison T. Vidimos and Shlomo A. Koyfman

      Version of Record online: 7 FEB 2017 | DOI: 10.1002/cncr.30601

      • image
      • image
      • image

      Immunosuppressed patients with cutaneous squamous cell carcinoma of the head and neck have dramatically inferior outcomes compared with immunocompetent patients, despite bimodality therapy. Immune status is a strong prognostic factor that should be accounted for in prognostic systems, treatment algorithms, and clinical trial design.

    8. Disease Site

      Hematologic Malignancies
      Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

      Preetesh Jain, Philip A. Thompson, Michael Keating, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Hagop Kantarjian, Jan A. Burger, Susan O'Brien and William G. Wierda

      Version of Record online: 7 FEB 2017 | DOI: 10.1002/cncr.30596

      • image

      At nearly 4 years of follow-up, patients with chronic lymphocytic leukemia who progress and/or transform on ibrutinib therapy have poor outcomes. It is essential to delineate the pattern of mutations and dynamics of clonal evolution in patients who discontinue ibrutinib because of disease progression/transformation and to identify novel pathways for therapeutic targeting to improve their survival.

    9. Genitourinary Disease
      Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma

      Ryan P. Kopp, Kelly L. Stratton, Emily Glogowski, Kasmintan A. Schrader, Rohini Rau-Murthy, Paul Russo, Jonathan A. Coleman and Kenneth Offit

      Version of Record online: 7 FEB 2017 | DOI: 10.1002/cncr.30605

      Prospective pathologic evaluation of kidney tumors may identify cases that are suspicious for hereditary leiomyomatosis and renal cell carcinoma–associated renal cell carcinoma, which remains a very lethal form of kidney cancer. In this series, cases with suspicious pathologic features are significantly associated with positive testing for fumarate hydratase mutations (diagnostic of hereditary leiomyomatosis and renal cell carcinoma) when they are referred for clinical genetic testing.

    10. Discipline

      Epidemiology
      The American Cancer Society's Cancer Prevention Study 3 (CPS-3): Recruitment, study design, and baseline characteristics

      Alpa V. Patel, Eric J. Jacobs, Daniela M. Dudas, Peter J. Briggs, Cari J. Lichtman, Elizabeth B. Bain, Victoria L. Stevens, Marjorie L. McCullough, Lauren R. Teras, Peter T. Campbell, Mia M. Gaudet, Elizabeth G. Kirkland, Melissa H. Rittase, Nance Joiner, W. Ryan Diver, Janet S. Hildebrand, Nancy C. Yaw and Susan M. Gapstur

      Version of Record online: 7 FEB 2017 | DOI: 10.1002/cncr.30561

      • image
      • image

      The American Cancer Society has recruited a new, prospective cohort study, Cancer Prevention Study 3, of 303,682 adult men and women between 2006 and 2013 from 35 states and Puerto Rico. Participants provided a blood sample and extensive epidemiologic data at enrollment and will be followed for incident cancers and for cause-specific mortality for at least the next 20 years.

    11. Survivorship
      Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator

      Vicky Lehmann, Marrit A. Tuinman, Madelaine C. Keim, Adrien M. Winning, Randal S. Olshefski, Rajinder P.S. Bajwa, Mariët Hagedoorn and Cynthia A. Gerhardt

      Version of Record online: 6 FEB 2017 | DOI: 10.1002/cncr.30513

      The results of the current study indicate that adult survivors of childhood cancer do not differ from healthy controls with regard to their psychosexual development, sexual satisfaction, and relationship status satisfaction. However, more intense neurotoxic treatment appears to be associated with a higher risk of psychosexual impairment, and may be a more meaningful risk indicator than diagnostic category alone.

    12. Disease Site

      Genitourinary Disease
      Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract

      Piotr Zareba, Barak Rosenzweig, Andrew G. Winer and Jonathan A. Coleman

      Version of Record online: 2 FEB 2017 | DOI: 10.1002/cncr.30516

      • image
      • image

      In the current study, the National Cancer Data Base is used to assess the relationship between the extent of lymph node dissection performed at the time of radical nephroureterectomy for upper tract urothelial carcinoma and overall survival. Among a cohort of 2926 patients, a higher lymph node yield is found to be associated with lower all-cause mortality after adjustment for patient, tumor, and facility characteristics.

    13. Discipline

      Radiation Oncology
      Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques

      Yu-Chun Yen, Jer-Hwa Chang, Wei-Cheng Lin, Jeng-Fong Chiou, Yin-Chun Chang, Chia-Lun Chang, Han-Lin Hsu, Jyh-Ming Chow, Kevin Sheng-Po Yuan, Alexander T. H. Wu and Szu-Yuan Wu

      Version of Record online: 2 FEB 2017 | DOI: 10.1002/cncr.30565

      • image
      • image

      The therapeutic effects of esophagectomy using modern clinical staging and radiotherapy (RT) techniques and suitable RT doses are evaluated in patients with thoracic esophageal squamous cell carcinoma. This is the first study to demonstrate the effectiveness of esophagectomy in those who undergo esophagectomy and receive definitive RT or concurrent chemoradiotherapy using modern, intensity-modulated RT techniques.

  42. Review Articles

    1. The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies

      Andreas Pettersson, Travis Gerke, Katja Fall, Yudi Pawitan, Lars Holmberg, Edward L. Giovannucci, Philip W. Kantoff, Hans-Olov Adami, Jennifer R. Rider, Lorelei A. Mucci and on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)

      Version of Record online: 2 FEB 2017 | DOI: 10.1002/cncr.30582

      • image
      • image

      Markers that distinguish patients who would benefit from or could avoid radical treatment would improve prostate cancer management. In this article, the authors put forth a conceptual classification system of patients with prostate cancer that can aid in the design and interpretation of prognostic biomarker studies.

  43. Original Articles

    1. Disease Site

      Soft Tissue and Bone Sarcoma
      Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group

      Andrea J. MacNeill, Rosalba Miceli, Dirk C. Strauss, Sylvie Bonvalot, Peter Hohenberger, Frits Van Coevorden, Piotr Rutkowski, Dario Callegaro, Andrew J. Hayes, Charles Honoré, Mark Fairweather, Amanda Cannell, Jens Jakob, Rick L. Haas, Milena Szacht, Marco Fiore, Paolo G. Casali, Raphael E. Pollock, Chandrajit P. Raut, Alessandro Gronchi and Carol J. Swallow

      Version of Record online: 2 FEB 2017 | DOI: 10.1002/cncr.30572

      • image
      • image
      • image

      In this multi-institutional series of 408 patients with recurrent retroperitoneal sarcoma treated at specialist centers, relapse is shown to be associated with considerable disease-specific mortality, with 5-year overall survival ranging from 12% to 28% according to the pattern of failure. Select patients with recurrent or metastatic disease should be considered for resection.

  44. Listen to the Patient

    1. Discussing molecular testing in oncology care: Comparing patient and physician information preferences

      Ana P. M. Pinheiro, Rachel H. Pocock, Jeffrey M. Switchenko, Margie D. Dixon, Walid L. Shaib, Suresh S. Ramalingam and Rebecca D. Pentz

      Version of Record online: 31 JAN 2017 | DOI: 10.1002/cncr.30494

      This study provides important information regarding the topics that cancer patients perceive as the most relevant in their discussions on molecular testing. The authors recommend that their 12 preferred topics be discussed.

  45. Original Articles

    1. Disease Site

      Genitourinary Disease
      Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes

      Hyun Kim, Ingrid Kalchman, María Santiago-Jiménez, Jonathan Lehrer, Jenny Guo, Gretchen Hermann, Kosj Yamoah, Mohammed Alshalalfa, Huei-Chung Huang, Ashley E. Ross, Edward M. Schaeffer, Elai Davicioni, Nicholas Erho, Kasra Yousefi and Robert B. Den

      Version of Record online: 31 JAN 2017 | DOI: 10.1002/cncr.30580

      • image
      • image
      • image

      In a genomic analysis of 477 prostatectomy specimens, metabolic gene expression, but not body mass index, is associated with prostate cancer metastases.

    2. Factors predicting prostate cancer upgrading on magnetic resonance imaging–targeted biopsy in an active surveillance population

      Win Shun Lai, Jennifer B. Gordetsky, John V. Thomas, Jeffrey W. Nix and Soroush Rais-Bahrami

      Version of Record online: 31 JAN 2017 | DOI: 10.1002/cncr.30548

      • image
      • image

      The integration of magnetic resonance imaging findings with clinical parameters can add value to a model predicting upgrading from a Gleason score of 3 + 3 = 6 in men on active surveillance. This can potentially be used as a noninvasive approach for confirming active-surveillance patients with low-risk disease for whom biopsy may be deferred.

  46. Commentary

    1. Pathfinders in oncology from the end of the Middle Ages to the beginning of the 19th century

      Steven I. Hajdu

      Version of Record online: 31 JAN 2017 | DOI: 10.1002/cncr.30590

      • image
      • image
      • image
      • image
      • image
      • image

      During the 3 centuries reviewed herein, all that was known regarding cancer was limited to Italy, France, Germany, and England. The biographies and historical backgrounds of 7 pioneer physicians who contributed the most to the progression of oncology from the end of the Middle Ages to the beginning of the 19th century are presented.

  47. Original Articles

    1. Discipline

      Disparities Research
      Survival of patients with head and neck squamous cell carcinoma by housing subsidy in a tiered public housing system

      Ting Hway Wong, Thakshayeni Skanthakumar, Nivedita Nadkarni, Hai Van Nguyen and N. Gopalakrishna Iyer

      Version of Record online: 30 JAN 2017 | DOI: 10.1002/cncr.30557

      • image
      • image

      Socioeconomic status affects survival in patients with head and neck cancer, even in health systems with universal health care. By using the tiered, subsidized housing system in Singapore as a proxy for socioeconomic status, the results from this study indicate that patients who reside in smaller, higher subsidy apartments have worse survival despite similar disease stage at presentation.

    2. Epidemiology
      Alcohol intake and mortality among survivors of colorectal cancer: The Cancer Prevention Study II Nutrition Cohort

      Baiyu Yang, Susan M. Gapstur, Christina C. Newton, Eric J. Jacobs and Peter T. Campbell

      Version of Record online: 30 JAN 2017 | DOI: 10.1002/cncr.30556

      Prediagnosis and postdiagnosis alcohol consumption generally do not appear to be associated with all-cause mortality among patients with colorectal cancer. However, there is some suggestion of increased colorectal cancer-specific mortality with postdiagnosis drinking, especially if consumed in higher amounts. To the authors' knowledge, the current study is the first to simultaneously examine both prediagnosis and postdiagnosis alcohol consumption in relation to colorectal cancer survival.

    3. Disease Site

      Breast Disease
      Mammographic breast density is associated with the development of contralateral breast cancer

      Akshara Raghavendra, Arup K. Sinha, Huong T. Le-Petross, Naveen Garg, Limin Hsu, Modesto Patangan Jr, Therese Bartholomew Bevers, Yu Shen, Arun Banu, Debu Tripathy, Isabelle Bedrosian and Carlos H. Barcenas

      Version of Record online: 30 JAN 2017 | DOI: 10.1002/cncr.30573

      • image

      The relationship between breast tissue density and contralateral breast cancer remains unknown. In the current study, the authors hypothesize that patients with dense mammographic breast density at the time of breast cancer diagnosis will have an increased risk of developing metachronous contralateral breast cancer.

    4. Discipline

      Outcomes Research
      Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis

      Fotios V. Michelis, Vikas Gupta, Mei-Jie Zhang, Hai-Lin Wang, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjaneh, Yi-Bin Chen, Zachariah DeFilipp, Robert Peter Gale, Partow Kebriaei, Mohamed Kharfan-Dabaja, Hillard M. Lazarus, Taiga Nishihori, Richard F. Olsson, Betul Oran, Armin Rashidi, David A. Rizzieri, Martin S. Tallman, Marcos de Lima, H. Jean Khoury, Brenda M. Sandmaier, Daniel Weisdorf, Wael Saber and for the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaboration between the National Marrow Donor Program/Be the Match Registry and theMedicalCollegeofWisconsin

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30567

      • image
      • image
      • image
      • image

      Allogeneic transplantation offers significant curative potential for acute myeloid leukemia patients 60 years of age or older in their second complete remission. Unfavorable cytogenetic risk is the predominant adverse factor influencing survival in these patients.

    5. Disease Site

      Gynecologic Oncology
      Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer

      Harinder Brar, Liat Hogen and Al Covens

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30509

      • image
      • image

      Sentinel lymph node biopsy using technetium 99 (Tc99) and blue dye with ultrastaging is considered the most cost-effective strategy with respect to 5-year progression-free survival and morbidity-free survival. Although it is included only as an exploratory strategy in this study, sentinel lymph node biopsy with indocyanine green has the potential to be the most cost-effective strategy.

VIEW

  1. 1 - 100
  2. 101 - 144

SEARCH

SEARCH BY CITATION